Sirnaomics Advances STP705 for Squamous Cell Carcinoma In Situ into Late-Stage Clinical Development

Sirnaomics, a biopharmaceutical company focused on discovering and developing innovative drugs for indications with medical needs and large market opportunities, has announced the advancement of STP705 into late-stage clinical development for the treatment of Squamous Cell Carcinoma in situ (isSCC). The decision follows encouraging Phase IIa and Phase IIb clinical results that were shared with t..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 20.
  • textsms

Valneva Reports Strong Phase III Chikungunya Vaccine Data After Merck’s Exit from Race

French company Valneva has released positive results from a Phase III study of its chikungunya vaccine candidate VLA1553, following Merck's exit from the race earlier this year. The vaccine showed a 28-day seroprotection rate of 98.9% in participants given the inoculation, according to results published in medical journal The Lancet. However, more than half of those vaccinated developed at least..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 14.
  • textsms